Esomeprazole alone compared with esomeprazole plus aspirin for the treatment of aspirin-related peptic ulcers. 2012

Chun-Peng Liu, and Wen-Chi Chen, and Kwok-Hung Lai, and Guang-Yuan Mar, and Shyr-Yi Lin, and Luo-Ping Ger, and Ping-I Hsu, and
Department of Internal Medicine, Kaohsiung Veterans General Hospital and National Yang-Ming University, Kaohsiung, Taiwan, ROC.

BACKGROUND Aspirin-related peptic ulcers are a common disorder. However, whether or not aspirin should be continued during treatment for aspirin-related ulcers remains unclear. OBJECTIVE To compare esomeprazole alone with esomeprazole plus aspirin in the treatment of aspirin-related peptic ulcers and to investigate the independent factors associated with the failure of ulcer healing. METHODS From January 2008 to July 2011, patients with aspirin-related peptic ulcers were randomized to receive esomeprazole (40 mg per day) alone or esomeprazole (40 mg per day) plus aspirin (100 mg per day) for 8 weeks. The subjects with Helicobacter pylori infection were treated with standard triple therapy. Follow-up endoscopy was carried out at the end of the 8th week. The primary end point was the healing of peptic ulcers. RESULTS In all, 178 patients (89 receiving esomeprazole alone and 89 receiving esomeprazole plus aspirin) were enrolled and underwent follow-up endoscopy. The healing rate of ulcers by modified intention-to-treat analysis was 82.5% (95% confidence interval (CI), 74.2-90.8%) among patients treated with esomeprazole alone and 81.5% (95% CI, 73.0-90.0%) among patients treated with esomeprazole plus aspirin (difference, 1.0%; 95% CI, -11.2 to 12.6%). The per-protocol analysis yielded similar results (healing rate: 83.1% vs. 83.8%, respectively; difference, 0.7%; 95% CI, -11.2 to 12.6%). Multivariate analysis disclosed that use of steroids during treatment (odds ratio: 5.6; 95% CI, 1.1-27.7%) was the only independent factor associated with the failure of ulcer healing. CONCLUSIONS The observed ulcer healing rates were comparable in the esomeprazole and esomeprazole-plus-aspirin groups, but the wide CIs do not rule out clinically meaningful differences of more than 10%.

UI MeSH Term Description Entries
D008297 Male Males
D010437 Peptic Ulcer Ulcer that occurs in the regions of the GASTROINTESTINAL TRACT which come into contact with GASTRIC JUICE containing PEPSIN and GASTRIC ACID. It occurs when there are defects in the MUCOSA barrier. The common forms of peptic ulcers are associated with HELICOBACTER PYLORI and the consumption of nonsteroidal anti-inflammatory drugs (NSAIDS). Gastroduodenal Ulcer,Marginal Ulcer,Gastroduodenal Ulcers,Marginal Ulcers,Peptic Ulcers,Ulcer, Gastroduodenal,Ulcer, Marginal,Ulcer, Peptic,Ulcers, Gastroduodenal,Ulcers, Marginal,Ulcers, Peptic
D010975 Platelet Aggregation Inhibitors Drugs or agents which antagonize or impair any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system. Antiaggregants, Platelet,Antiplatelet Agent,Antiplatelet Agents,Antiplatelet Drug,Blood Platelet Aggregation Inhibitor,Blood Platelet Antagonist,Blood Platelet Antiaggregant,PAR-1 Antagonists,Platelet Aggregation Inhibitor,Platelet Antagonist,Platelet Antagonists,Platelet Antiaggregant,Platelet Antiaggregants,Platelet Inhibitor,Protease-Activated Receptor-1 Antagonists,Antiplatelet Drugs,Blood Platelet Aggregation Inhibitors,Blood Platelet Antagonists,Blood Platelet Antiaggregants,Platelet Inhibitors,Agent, Antiplatelet,Aggregation Inhibitor, Platelet,Antagonist, Blood Platelet,Antagonist, Platelet,Antiaggregant, Blood Platelet,Antiaggregant, Platelet,Drug, Antiplatelet,Inhibitor, Platelet,Inhibitor, Platelet Aggregation,PAR 1 Antagonists,Platelet Antagonist, Blood,Platelet Antiaggregant, Blood,Protease Activated Receptor 1 Antagonists
D011795 Surveys and Questionnaires Collections of data obtained from voluntary subjects. The information usually takes the form of answers to questions, or suggestions. Community Survey,Nonrespondent,Questionnaire,Questionnaires,Respondent,Survey,Survey Method,Survey Methods,Surveys,Baseline Survey,Community Surveys,Methodology, Survey,Nonrespondents,Questionnaire Design,Randomized Response Technique,Repeated Rounds of Survey,Respondents,Survey Methodology,Baseline Surveys,Design, Questionnaire,Designs, Questionnaire,Methods, Survey,Questionnaire Designs,Questionnaires and Surveys,Randomized Response Techniques,Response Technique, Randomized,Response Techniques, Randomized,Survey, Baseline,Survey, Community,Surveys, Baseline,Surveys, Community,Techniques, Randomized Response
D002318 Cardiovascular Diseases Pathological conditions involving the CARDIOVASCULAR SYSTEM including the HEART; the BLOOD VESSELS; or the PERICARDIUM. Adverse Cardiac Event,Cardiac Events,Major Adverse Cardiac Events,Adverse Cardiac Events,Cardiac Event,Cardiac Event, Adverse,Cardiac Events, Adverse,Cardiovascular Disease,Disease, Cardiovascular,Event, Cardiac
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D000897 Anti-Ulcer Agents Various agents with different action mechanisms used to treat or ameliorate PEPTIC ULCER or irritation of the gastrointestinal tract. This has included ANTIBIOTICS to treat HELICOBACTER INFECTIONS; HISTAMINE H2 ANTAGONISTS to reduce GASTRIC ACID secretion; and ANTACIDS for symptomatic relief. Anti-Ulcer Drugs,Agents, Anti-Ulcer,Anti Ulcer Agents,Anti Ulcer Drugs,Drugs, Anti-Ulcer

Related Publications

Chun-Peng Liu, and Wen-Chi Chen, and Kwok-Hung Lai, and Guang-Yuan Mar, and Shyr-Yi Lin, and Luo-Ping Ger, and Ping-I Hsu, and
January 2006, Gaceta sanitaria,
Chun-Peng Liu, and Wen-Chi Chen, and Kwok-Hung Lai, and Guang-Yuan Mar, and Shyr-Yi Lin, and Luo-Ping Ger, and Ping-I Hsu, and
January 2008, Medscape journal of medicine,
Chun-Peng Liu, and Wen-Chi Chen, and Kwok-Hung Lai, and Guang-Yuan Mar, and Shyr-Yi Lin, and Luo-Ping Ger, and Ping-I Hsu, and
March 2011, Gastroenterology,
Chun-Peng Liu, and Wen-Chi Chen, and Kwok-Hung Lai, and Guang-Yuan Mar, and Shyr-Yi Lin, and Luo-Ping Ger, and Ping-I Hsu, and
January 2011, Annals of gastroenterology,
Chun-Peng Liu, and Wen-Chi Chen, and Kwok-Hung Lai, and Guang-Yuan Mar, and Shyr-Yi Lin, and Luo-Ping Ger, and Ping-I Hsu, and
December 1995, The American journal of clinical nutrition,
Chun-Peng Liu, and Wen-Chi Chen, and Kwok-Hung Lai, and Guang-Yuan Mar, and Shyr-Yi Lin, and Luo-Ping Ger, and Ping-I Hsu, and
February 2004, Alimentary pharmacology & therapeutics,
Chun-Peng Liu, and Wen-Chi Chen, and Kwok-Hung Lai, and Guang-Yuan Mar, and Shyr-Yi Lin, and Luo-Ping Ger, and Ping-I Hsu, and
July 2017, Annals of internal medicine,
Chun-Peng Liu, and Wen-Chi Chen, and Kwok-Hung Lai, and Guang-Yuan Mar, and Shyr-Yi Lin, and Luo-Ping Ger, and Ping-I Hsu, and
June 2008, Clinical journal of gastroenterology,
Chun-Peng Liu, and Wen-Chi Chen, and Kwok-Hung Lai, and Guang-Yuan Mar, and Shyr-Yi Lin, and Luo-Ping Ger, and Ping-I Hsu, and
January 2024, American journal of cardiovascular drugs : drugs, devices, and other interventions,
Chun-Peng Liu, and Wen-Chi Chen, and Kwok-Hung Lai, and Guang-Yuan Mar, and Shyr-Yi Lin, and Luo-Ping Ger, and Ping-I Hsu, and
November 2017, Annals of internal medicine,
Copied contents to your clipboard!